TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
13 mai 2024 07h00 HE
|
TScan Therapeutics, Inc.
First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with...
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
09 mai 2024 07h00 HE
|
TScan Therapeutics, Inc.
Patient dosed with TSC-203-A0201 targeting cancer-associated antigen PRAME On-track to report initial data from the solid tumor clinical trial in 2024 WALTHAM, Mass., May ...
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
24 avr. 2024 16h05 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
24 avr. 2024 11h03 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
22 avr. 2024 17h01 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Closing of Upsized Public Offering
19 avr. 2024 10h05 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
17 avr. 2024 00h30 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
16 avr. 2024 16h25 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
16 avr. 2024 16h01 HE
|
TScan Therapeutics, Inc.
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex...
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
08 avr. 2024 08h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...